EA201301029A1 - Диагностический анализ на основе антител - Google Patents
Диагностический анализ на основе антителInfo
- Publication number
- EA201301029A1 EA201301029A1 EA201301029A EA201301029A EA201301029A1 EA 201301029 A1 EA201301029 A1 EA 201301029A1 EA 201301029 A EA201301029 A EA 201301029A EA 201301029 A EA201301029 A EA 201301029A EA 201301029 A1 EA201301029 A1 EA 201301029A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- analysis based
- diagnostic analysis
- antibody
- disease
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
Abstract
В заявке описаны новые диагностические анализы, предназначенные для диагностирования амилоидоза, в частности болезни Альцгеймера, и родственных состояний. В частности описаны моноклональные антитела и анализ на основе антител.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161453449P | 2011-03-16 | 2011-03-16 | |
PCT/EP2012/054629 WO2012123562A1 (en) | 2011-03-16 | 2012-03-16 | Diagnostic antibody assay |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201301029A1 true EA201301029A1 (ru) | 2014-05-30 |
EA032054B1 EA032054B1 (ru) | 2019-04-30 |
Family
ID=45833428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201301029A EA032054B1 (ru) | 2011-03-16 | 2012-03-16 | Моноклональное антитело или его антигенсвязывающий фрагмент, его применения, клеточная линия гибридомы для его получения, фармацевтическая композиция, содержащая моноклональное антитело или его антигенсвязывающий фрагмент, способ диагностики in vitro амилоид-ассоциированного заболевания и набор для его осуществления |
Country Status (15)
Country | Link |
---|---|
US (2) | US8809508B2 (ru) |
EP (1) | EP2686346B1 (ru) |
JP (1) | JP6220675B2 (ru) |
KR (1) | KR102020072B1 (ru) |
CN (1) | CN103459421B (ru) |
AU (1) | AU2012228236B2 (ru) |
BR (1) | BR112013023211B1 (ru) |
CA (1) | CA2828433C (ru) |
DK (1) | DK2686346T3 (ru) |
EA (1) | EA032054B1 (ru) |
IL (1) | IL227847A0 (ru) |
MX (1) | MX343873B (ru) |
SG (1) | SG192805A1 (ru) |
WO (1) | WO2012123562A1 (ru) |
ZA (1) | ZA201305946B (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2970235B1 (en) | 2013-03-15 | 2019-06-19 | Probiodrug AG | Novel inhibitors |
EP3234611A1 (en) | 2014-12-19 | 2017-10-25 | Probiodrug AG | Novel method for the detection of pglu-abeta peptides |
KR20180030653A (ko) * | 2015-07-16 | 2018-03-23 | 프로비오드룩 아게 | 항-피로글루타메이트화된 아밀로이드 베타 인간화 항체 |
JP2022550017A (ja) * | 2019-10-01 | 2022-11-30 | レプリゲン・コーポレーション | 流体におけるタンパク質濃度の決定 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
CN1414976A (zh) * | 1999-12-08 | 2003-04-30 | 明德塞特生物制药(美国)公司 | 作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法 |
US7117096B2 (en) * | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
AU2003250102B2 (en) | 2002-07-24 | 2009-09-17 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
WO2004029629A1 (en) | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
KR101099206B1 (ko) | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
ES2259270B1 (es) | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
WO2008002893A2 (en) | 2006-06-29 | 2008-01-03 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
DK2091945T3 (da) | 2006-11-09 | 2014-04-22 | Probiodrug Ag | Nye inhibitorer af glutaminylcyclase |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
JP5599614B2 (ja) | 2006-11-09 | 2014-10-01 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
EP2118101B1 (en) | 2007-03-09 | 2012-09-26 | Probiodrug AG | Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
EP2160380B1 (en) | 2007-04-18 | 2014-04-02 | Probiodrug AG | Cyano-guanidine derivatives as glutaminyl cyclase inhibitors |
DK2160389T3 (da) | 2007-04-18 | 2014-06-23 | Probiodrug Ag | Thioxoquinazolinonderivater som glutaminylcyclaseinhibitorer |
EP2146968B1 (en) | 2007-04-18 | 2015-09-23 | Probiodrug AG | Urea derivatives as glutaminyl cyclase inhibitors |
WO2008128981A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors |
JP5676249B2 (ja) | 2007-04-20 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体 |
MX2010004179A (es) * | 2007-10-15 | 2010-08-04 | Janssen Pharmaceutica Nv | Anticuerpos anti-amiloide, composiciones, metodos y usos. |
AT506820B1 (de) * | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
BRPI0916366B1 (pt) * | 2008-07-21 | 2021-08-10 | Probiodrug Ag | Anticorpo que se liga às variantes de peptídeos abeta, sua composição, seu uso, seu kit de diagnóstico, e linhagem celular de hibridoma |
WO2010128139A1 (en) * | 2009-05-08 | 2010-11-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment |
EP3892633A1 (en) * | 2009-06-29 | 2021-10-13 | BioArctic AB | Antibodies selective for n-terminaltruncated amyloid-p protofibrils/oligomers |
-
2012
- 2012-03-16 KR KR1020137023118A patent/KR102020072B1/ko active IP Right Grant
- 2012-03-16 US US13/422,583 patent/US8809508B2/en active Active
- 2012-03-16 JP JP2013558453A patent/JP6220675B2/ja active Active
- 2012-03-16 BR BR112013023211-0A patent/BR112013023211B1/pt active IP Right Grant
- 2012-03-16 MX MX2013010571A patent/MX343873B/es active IP Right Grant
- 2012-03-16 WO PCT/EP2012/054629 patent/WO2012123562A1/en active Application Filing
- 2012-03-16 CA CA2828433A patent/CA2828433C/en active Active
- 2012-03-16 SG SG2013062286A patent/SG192805A1/en unknown
- 2012-03-16 EA EA201301029A patent/EA032054B1/ru not_active IP Right Cessation
- 2012-03-16 CN CN201280013607.2A patent/CN103459421B/zh active Active
- 2012-03-16 AU AU2012228236A patent/AU2012228236B2/en active Active
- 2012-03-16 EP EP12708855.7A patent/EP2686346B1/en active Active
- 2012-03-16 DK DK12708855.7T patent/DK2686346T3/en active
-
2013
- 2013-08-07 ZA ZA2013/05946A patent/ZA201305946B/en unknown
- 2013-08-07 IL IL227847A patent/IL227847A0/en active IP Right Grant
-
2014
- 2014-05-19 US US14/280,919 patent/US9657089B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN103459421B (zh) | 2017-07-14 |
US8809508B2 (en) | 2014-08-19 |
SG192805A1 (en) | 2013-09-30 |
JP6220675B2 (ja) | 2017-11-01 |
KR20140006019A (ko) | 2014-01-15 |
NZ614217A (en) | 2015-12-24 |
AU2012228236B2 (en) | 2016-10-27 |
WO2012123562A1 (en) | 2012-09-20 |
KR102020072B1 (ko) | 2019-11-04 |
BR112013023211B1 (pt) | 2022-11-08 |
ZA201305946B (en) | 2014-10-29 |
MX2013010571A (es) | 2013-12-02 |
CA2828433A1 (en) | 2012-09-20 |
DK2686346T3 (en) | 2017-03-27 |
CA2828433C (en) | 2020-08-04 |
BR112013023211A2 (pt) | 2016-11-22 |
MX343873B (es) | 2016-11-25 |
US20140255414A1 (en) | 2014-09-11 |
EA032054B1 (ru) | 2019-04-30 |
EP2686346A1 (en) | 2014-01-22 |
IL227847A0 (en) | 2013-09-30 |
US9657089B2 (en) | 2017-05-23 |
JP2014509860A (ja) | 2014-04-24 |
US20120237529A1 (en) | 2012-09-20 |
AU2012228236A1 (en) | 2013-10-03 |
CN103459421A (zh) | 2013-12-18 |
EP2686346B1 (en) | 2016-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201100231A1 (ru) | Диагностический анализ на основе антител | |
CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
PH12016500658B1 (en) | Human anti-alpha-synuclein autoantibodies | |
CO6710903A2 (es) | Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo | |
EA201690310A1 (ru) | Антитела, связывающие cd27 человека, и их применение | |
CL2014000574A1 (es) | Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano. | |
NZ760022A (en) | Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor | |
EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
EA201400579A1 (ru) | Антитела к il-36r | |
BR112013023540A2 (pt) | anticorpo, kit e método para a determinação de peptídeos amilóides | |
ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
EA201390933A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
BR112012007365A2 (pt) | proteínas de ligação à il-1 | |
EA201300530A1 (ru) | Антитела к il-23 | |
BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
EA201390453A1 (ru) | Человеческие анти-тау антитела | |
EA201590459A1 (ru) | Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение | |
CR20110559A (es) | Anticuerpos específicos para cadherina-17 | |
CA2839777C (en) | Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease | |
BR112012019475A2 (pt) | "uso de um anticorpo monoclonal anti-cd 44 anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra | |
TR201819828T4 (tr) | Anti-fosfolipaz d4 antikoru. | |
EA201301029A1 (ru) | Диагностический анализ на основе антител | |
TR201900550T4 (tr) | İnsan p53'ünün bir lineer epitopunu bağlayan antikor ve bunun tanısal uygulamaları. | |
EA201100253A1 (ru) | Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний | |
AR112975A2 (es) | Anticuerpo humanizado |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KG TM |
|
TC4A | Change in name of a patent proprietor in a eurasian patent | ||
PD4A | Registration of transfer of a eurasian patent in accordance with the succession in title |